What precision dx are available for stage 4 pancreatic cancer, esp with kras mutation

For stage 4 pancreatic cancer, especially with a KRAS mutation, there are several precision diagnostic tests available that can help guide treatment decisions. However, it's important to note that guidelines may have some limitations regarding the latest advancements for this specific scenario.

According to the National Comprehensive Cancer Network (NCCN) Guidelines for Pancreatic Adenocarcinoma (Version 2.2022), the following biomarker testing is recommended:

• Testing for mismatch repair deficiency or microsatellite instability for patients with metastatic disease to guide the use of pembrolizumab.

• Broad molecular profiling, including testing for KRAS mutations, is recommended for patients with good performance status where the results could guide future treatment options.

The NCCN states that KRAS mutations are found in over 90% of pancreatic adenocarcinomas and are associated with a more aggressive biology. However, KRAS mutations alone are not currently actionable for FDA-approved therapies.

From the American Society of Clinical Oncology (ASCO), some additional insights:

• Testing pancreatic cancer tissue for specific genetic mutations, including KRAS, is recommended to help determine if a patient may benefit from a clinical trial studying a targeted therapy.

• While KRAS mutations are very common in pancreatic cancer, directly targeting mutant KRAS has proven difficult so far. However, there is ongoing research into therapies that may work in KRAS-mutated cancers indirectly.

In summary, while KRAS mutation testing is recommended for pancreatic cancer to explore clinical trial options, there are currently no FDA-approved precision therapies specifically for KRAS-mutated pancreatic cancer outside of a trial setting. Testing for other biomarkers and broad molecular profiling is also advised per guidelines to evaluate potential treatment options.